Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) has received the establishment inspection report (EIR) from the US Food and Drug Administration for its API manufacturing facility at Ambernath in Maharashtra, India, according to a Wednesday filing to the Indian stock exchanges.
The US FDA inspected the unit between Feb. 10 and Feb. 14, which ended with zero observations.
Therefore, the EIR report has been classified as 'no action indicated.'
The company's shares were up nearly 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.